NCT05160922 is a Phase 4 clinical trial of crizotinib in NSCLC, sponsored by Pfizer.

Who is sponsoring NCT05160922?

NCT05160922 is sponsored by Pfizer.

What drugs are being tested in NCT05160922?

Interventions in NCT05160922: crizotinib.

What condition does NCT05160922 study?

NCT05160922 studies NSCLC, ALCL, IMT.

Is NCT05160922 still recruiting?

NCT05160922 is currently active, enrolled. Last updated 30 March 2026.

Last reviewed 2026-03-30 · How we verify

NCT05160922

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Crizotinib Continuation Clinical Study

Active, enrolled Phase 4 Last updated 30 March 2026

What this trial tests

Phase 4 trial testing crizotinib in NSCLC in 27 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

27 December 2021

Primary endpoint
21 March 2028

21 March 2028

Quick facts

Lead sponsor	Pfizer
Phase	Phase 4
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	27
Start date	27 December 2021
Primary completion	21 March 2028
Estimated completion	21 March 2028
Sites	13 locations across Italy, Japan, Russia, Taiwan, China

Drugs / interventions tested

crizotinib (crizotinib) — full drug profile →

Conditions studied

NSCLC — all drugs for NSCLC →
ALCL — all drugs for ALCL →
IMT — all drugs for IMT →

Sponsor

Pfizer — full company profile →

Who can join

0 and older, any sex, with NSCLC or ALCL. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this continuation study is to provide continued access to crizotinib treatment for eligible participants from a current Pfizer sponsored crizotinib clinical study that is planned to close.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Tumor biomarkers for diagnosis, prognosis and targeted therapy.
Zhou Y, Tao L, Qiu J, Xu J, et al · · 2024 · cited 379× · PMID 38763973 · DOI 10.1038/s41392-024-01823-2
Recent advances in the treatment of non-small cell lung cancer with MET inhibitors.
Zhang D, Zhang W, Liu H, Liu P, et al · · 2024 · cited 1× · PMID 39720556 · DOI 10.3389/fchem.2024.1501844

Verify or expand the search:

Other trials of crizotinib

Trials testing the same drug.

NCT05834348 — A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in N · completed
NCT04647110 — Real-world Therapy of ALK-positive NSCLC in Sweden: the Sequencing of ALK Tyrosine Kinase Inhibitor Drugs and Their Ther · completed
NCT04632758 — Study Comparing WX-0593 to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients · Phase 3 · unknown
NCT03375242 — Safety and Efficacy of Xalkori ROS1 · active not recruiting
NCT01999972 — A Phase 1b Study Of Axitinib In Combination With Crizotinib In Patients With Advanced Solid Tumors · Phase 1 · completed

Other recruiting trials for NSCLC

Currently open trials in the same condition.

NCT07479277 — Progel Platinum for Air Leak Reduction After VATS Lobectomy for NSCLC · NA · recruiting
NCT07323732 — A Study of BIO 300 and Thoracic Radiation Therapy in People With Non-Small Cell Lung Cancer and Interstitial Lung Diseas · Phase 2 · recruiting
NCT07274813 — A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX37 in Advanced/Metastatic Solid Tumors · EARLY_PHASE1 · recruiting
NCT07325864 — Molecular Phenotyping of Primitive Lung Cancer and Metastatic Site · recruiting
NCT07169552 — HC010 in First-line PD-L1 Positive Advanced NSCLC Patients · Phase 2 · recruiting

Other Pfizer trials

Trials by the same sponsor.

NCT04982848 — Korea Post Marketing Surveillance (PMS) Study of Talzenna® · not yet recruiting
NCT06873191 — A Study to Learn More About Tukysa Once it is Out in the Korean Market · not yet recruiting
NCT07497854 — A Study to Learn About the Study Medicine NURTEC® ODT 75 mg After it is Released Into the Markets in Korea · not yet recruiting
NCT06507904 — A Study to Learn How Different Preparations of Osivelotor Taste and Enter the Blood With Food or Liquids or With an Anta · Phase 1 · not yet recruiting
NCT06864585 — A Study to Learn About the Study Medicine - Zavicefta in Patients With Sepsis or Loss of Kidney Function in Japan · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05160922 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Pfizer
Last refreshed: 30 March 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05160922.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing